Table 3.
Results from the pathway analysis based on the altered metabolites in SPMS compared with RRMS patients.
| Pathway | Coverage | p-Value | FDR | Impact |
|---|---|---|---|---|
| Aminoacyl-tRNA biosynthesis | 6/56 | 4.2 × 10−4 | 0.034 | 0 |
| Phenylalanine metabolism | 4/45 | 2.9 × 10−3 | 0.103 | 0.173 |
| Tryptophan metabolism | 5/79 | 3.9 × 10−3 | 0.103 | 0.146 |
| Valine, leucine & isoleucine biosynthesis | 3/27 | 5.5 × 10−3 | 0.110 | 0.052 |
| Pyrimidine metabolism | 4/60 | 8.3 × 10−3 | 0.133 | 0.088 |
| Nitrogen metabolism | 3/39 | 0.015 | 0.188 | 0 |
| Valine, leucine & isoleucine degradation | 3/40 | 0.016 | 0.188 | 0.042 |
| Purine metabolism | 4/92 | 0.035 | 0.350 | 0.018 |